Autoimmunity and graves disease

R. S. Bahn

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations


Current treatment options for Graves hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.

Original languageEnglish (US)
Pages (from-to)577-579
Number of pages3
JournalClinical pharmacology and therapeutics
Issue number4
StatePublished - Apr 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Autoimmunity and graves disease'. Together they form a unique fingerprint.

Cite this